Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Dr. Paulson Discusses Acquired Resistance to Immunotherapy

Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Dorff on Current Agents for Patients With mCRPC

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses combining chemotherapy and immunotherapy as a treatment approach for patients with bladder cancer.

Dr. Grivas on Combining Chemotherapy and Immunotherapy in Bladder Cancer

Soft Tissue Sarcoma: An Increasing Number of Options

Second-Line Therapy Options: Role of Trabectedin

Soft Tissue Sarcoma: Decisions Following Progression

Changing Treatment Landscape in Soft Tissue Sarcoma

Olaratumab's Role in Soft Tissue Sarcoma

Soft Tissue Sarcoma: Selecting Among Frontline Options

First-line Options in Soft Tissue Sarcoma

Initial Treatment Approach in Soft Tissue Sarcoma

Common Pitfalls With Treating Soft Tissue Sarcoma

Collaboration of Experts in Soft Tissue Sarcoma

Ongoing Management Decisions in Soft Tissue Sarcoma

Multidisciplinary Team in Soft Tissue Sarcoma

How Sarcoma Experts Work With Community Oncologists

Histopathological Diagnosis in Soft Tissue Sarcoma

Heterogeneity of Soft Tissue Sarcomas

Johanna Bendell, MD, discusses the current and emerging treatment landscape of immunotherapy for patients with CRC.

Efforts Continue to Expand Immunotherapy in CRC

The combination of cabiralizumab and nivolumab resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer.

Novel Combination Shows Promising Responses in Pancreatic Cancer

Immuno-Oncology

Immuno-Oncology | Specialty